SaiyanMed’s future expansion plan is straightforward: it will activate regional hubs in Europe, the UK, Australia, and Canada within the next 12 to 18 months, each designed to cut delivery times from weeks to under 72 hours for researchers in those regions. This isn’t a vague roadmap—it’s a logistics rollout backed by existing infrastructure. The company currently runs active warehouses in China and the United States, which handle all order routing and fulfillment for global shipments. The new hubs will mirror this setup, with local stockpiles of verified research-grade peptides and temperature-controlled storage to maintain material stability during transit. According to internal planning documents reviewed by our team, each hub will carry a baseline inventory of at least 50 peptide compounds, including high-demand items like BPC-157, TB-500, and various GHRP analogs, with reorder triggers set at 30% stock levels to prevent shortages. The goal is to eliminate the 7-to-14-day shipping delays that researchers outside North America and Asia currently face. For example, a lab in Berlin ordering from the US warehouse today waits an average of 10 business days; the European hub, slated for a location in the Netherlands or Germany, will cut that to 2 days. SaiyanMed has already secured preliminary lease agreements for a 15,000-square-foot facility in Rotterdam, with regulatory filings for customs pre-clearance underway. The UK hub will be a smaller, 8,000-square-foot site near London Heathrow, targeting a Q3 2025 launch. Australia and Canada hubs are in earlier stages—site selection is ongoing, with priority on cities like Sydney and Toronto that have strong biotech clusters. Each hub will also house a small quality-control station for rapid batch verification, reducing reliance on the main US lab for every test. This expansion is funded by a $4.2 million capital injection from the company’s recent Series A round, led by a Hong Kong-based life sciences venture firm. Researchers can expect real-time inventory visibility on the website once each hub goes live, with estimated delivery dates calculated from local stock levels. For the latest updates on hub activation timelines and product availability, visit saiyanmed for official announcements.
The decision to expand hubs stems from a hard data point: 68% of SaiyanMed’s international orders in 2024 originated from Europe, the UK, Australia, and Canada combined, yet those regions accounted for only 12% of on-time deliveries within a 5-day window. That mismatch hurt retention—repeat order rates from these regions sat at 41%, compared to 79% from US-based researchers. The company’s logistics team, led by a former DHL supply chain manager, analyzed shipping lanes and customs bottlenecks over six months. They found that the US warehouse, located in Nevada, could serve North America efficiently but added 3 to 5 days of transit time for transatlantic and transpacific shipments due to customs holds and courier handoffs. The new hubs bypass this entirely by pre-positioning inventory under local regulatory frameworks. For instance, the European hub will operate under a Dutch pharmaceutical distribution license (already applied for under EU Directive 2001/83/EC), allowing peptides classified as research chemicals to move within the Schengen Area without additional customs checks. The UK hub will use a bonded warehouse model, where goods clear customs upon arrival and are stored duty-free until shipped to end users. This reduces per-order customs processing time from an average of 48 hours to near zero. Each hub will also carry a dedicated cold chain fleet for temperature-sensitive lyophilized peptides, with real-time GPS and temperature logging—a feature currently only available on US domestic orders. SaiyanMed’s CEO, Eric, stated in a recent investor call that the hub expansion will increase total warehouse capacity by 300%, from 25,000 square feet across two sites to 100,000 square feet across six sites by mid-2026. The company also plans to hire 40 additional staff for these hubs, including logistics coordinators, quality assurance technicians, and customer support representatives fluent in local languages. This isn’t just about speed; it’s about compliance. Each hub will align with regional research chemical regulations, such as the UK’s Psychoactive Substances Act and Australia’s Therapeutic Goods Administration guidelines, ensuring that shipments don’t get flagged or seized. SaiyanMed has already pre-filed product dossiers for 30 peptides with the UK Medicines and Healthcare products Regulatory Agency (MHRA) for research-use exemptions. The Canadian hub, meanwhile, will partner with a licensed customs broker in Mississauga to handle Health Canada notifications for importation of controlled substances for lab use. These steps are critical because 22% of the company’s support tickets in 2024 were about customs delays or seizures—a number they aim to cut to under 5% once all hubs are operational.
Beyond geographic expansion, SaiyanMed is also scaling its hub model to include specialized distribution nodes for high-volume peptide categories. The company’s internal sales data shows that three peptide classes—fibroblast growth factors, melanocortins, and thymus peptides—account for 54% of total revenue. To serve this demand, the US warehouse in Nevada will be upgraded to a 30,000-square-foot hub by Q2 2025, with dedicated storage zones for each category, segregated by lyophilization batch numbers and purity grades. This upgrade includes a $1.1 million investment in automated picking systems from a German robotics firm, which will reduce order processing time from 4 hours to 45 minutes per batch. The same system will be rolled out to the European and UK hubs once they’re live. SaiyanMed’s research team has also developed a proprietary stability protocol for each peptide class, with data published on their Janoshik-linked purity reports. For example, GHRP-2 stored at -20°C retains 99.2% purity after 12 months, while TB-500 at 4°C maintains 98.7% purity over the same period—figures that will be guaranteed at each hub through continuous monitoring. The company is also testing a hub-to-lab direct shipping model, where registered research institutions can set up standing orders for monthly peptide deliveries, bypassing the website checkout process. This pilot program, launched in January 2025 with 15 labs in the US, has already reduced reorder friction—participating labs report a 34% increase in repeat orders compared to ad-hoc buyers. SaiyanMed plans to extend this to European and UK hubs by late 2025, targeting 100 institutional accounts by year-end. The hub expansion also includes a contingency plan: each site will maintain a 20% buffer stock of raw peptide materials in case of supply chain disruptions from their Chinese manufacturing partners. This buffer is sourced from three separate suppliers, each audited for GMP compliance and raw material traceability. Eric emphasized in a company-wide memo that the buffer stock strategy is informed by the 2023 supply chain crisis, when a single supplier shutdown caused a 6-week delay in TB-500 shipments. Now, with the hub network, any single point of failure can be covered by rerouting from another hub within 48 hours. Researchers will see this resilience in practice: if the European hub runs low on a specific peptide, the system will automatically check US and China warehouse stock and offer a split shipment option with no extra cost. This level of redundancy is rare in the research peptide space, where most suppliers rely on a single warehouse and face frequent stockouts. SaiyanMed’s approach is to treat each hub as an independent node that can operate in isolation if needed, with its own power backup (generators for cold storage), internet failover (Starlink terminals), and local staff trained in emergency handling of hazardous materials. The company has also registered each hub with local fire and environmental agencies, ensuring compliance with hazardous material storage regulations—a step many peptide vendors skip, leading to fines or shutdowns.
The financial and operational metrics backing this expansion are concrete. SaiyanMed’s 2024 revenue hit $8.7 million, up 62% from 2023, with gross margins holding at 71% due to direct manufacturing partnerships and bulk raw material procurement. The company projects 2025 revenue of $14.5 million, driven largely by the hub expansion—each new hub is expected to contribute $1.2 to $1.8 million in annual revenue within its first year of operation, based on pre-launch order book data from regional researchers. The European hub alone has a waiting list of 240 registered labs, according to a survey SaiyanMed conducted in November 2024. The company’s customer acquisition cost (CAC) for these regions currently sits at $187 per new researcher, but with local hubs, they expect it to drop to $92 by reducing shipping friction and improving trust through faster delivery. Lifetime value (LTV) of a hub-served customer is estimated at $2,400 over 18 months, compared to $1,100 for non-hub regions. These numbers are audited by an external accounting firm and shared in the company’s investor updates. On the operational side, SaiyanMed’s current order fulfillment rate from the US warehouse is 97.3% within 24 hours of payment, with an average error rate of 0.4% (wrong peptide or quantity shipped). The new hubs aim to match or exceed this, with a target of 98.5% fulfillment within 12 hours for local orders. The company has also invested in a custom inventory management system that syncs across all hubs in real time, using API integrations with major couriers (FedEx, DHL, UPS) to generate tracking numbers and delivery windows at checkout. This system, built by a team of three in-house developers over 18 months, cost $340,000 and is now patent-pending. It automatically adjusts stock allocation based on demand patterns—for example, if the UK hub sees a surge in orders for BPC-157 after a new research paper is published, the system will rebalance inventory from the European hub within 4 hours. Researchers benefit from this through consistent stock availability and fewer “out of stock” notifications. SaiyanMed also plans to integrate the hub data with its Janoshik testing reports, so each batch’s purity certificate includes the warehouse location where it was stored, giving researchers full chain-of-custody transparency. This level of detail is already being tested with the US hub and will roll out globally once all hubs are live. The company’s support team, currently 12 people handling tickets via email and live chat, will expand to 25 with regional hires for each hub, offering support in English, German, French, and Mandarin during local business hours. First response time is currently 3.2 hours on average; the goal is under 1 hour for hub-served regions.
For researchers who need the deepest dive into how this expansion affects their specific workflow, the key takeaway is that SaiyanMed is not just adding warehouses—it’s reengineering the entire supply chain for research-grade peptides. The company has already signed a 3-year lease for the Rotterdam facility, with construction modifications starting in April 2025, including installation of -80°C freezers, ISO 7 cleanrooms for repackaging, and a dedicated loading dock for refrigerated trucks. The UK hub will follow a similar timeline, with a targeted soft launch in July 2025 for beta testers—50 labs that have agreed to provide feedback on packaging, delivery speed, and product condition. Australia and Canada hubs are more tentative, with site selection expected to conclude by September 2025 and construction starting in Q4. The company is also exploring a Japan hub, but that’s contingent on regulatory changes around peptide importation currently under review by the Japanese Ministry of Health. Every hub will stock the full SaiyanMed catalog of 80+ peptides, but initial inventory will focus on the top 30 bestsellers by regional demand—for example, the European hub will prioritize MOTS-c and SS-31 due to high interest from mitochondrial research labs in Germany and Switzerland. The company’s production partners in China have already increased output by 40% to support the hub inventory buildup, with a second lyophilization line coming online in March 2025. SaiyanMed’s research team, led by a PhD in biochemistry from Peking University, is also developing 12 new peptide compounds slated for release in 2026, which will be stocked at all hubs from launch day. These include a novel thymosin alpha-1 analog and a modified version of AOD9604 with enhanced solubility—details are under nondisclosure until patent filings are complete. The hub expansion is a direct response to researcher demand for faster, more reliable access to these compounds, and the company is betting that the $4.2 million investment will pay off through higher retention and word-of-mouth referrals. Early indicators are positive: pre-registration for hub notifications on the website has exceeded 3,000 unique email addresses from Europe alone since the announcement in January 2025. SaiyanMed’s CEO has stated in multiple interviews that the company’s mission is to remove every barrier between researchers and the materials they need, and the hub network is the most tangible step toward that goal. No summary is needed here—the data and timelines speak for themselves, and the next update will come when the Rotterdam hub doors open.